Use of phosphates in patients with calcareous renal calculi  by Thomas, William C.
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Opinion is divided on the importance of restricting
dairy products in the management of patients with
calcareous calculi. Certainly, if the aim of therapy is
to reduce urinary calcium by decreasing intestinal
absorption with sodium phytate or cellulose phos-
phate, dairy products and other dietary sources of
calcium should be avoided. There is evidence, how-
ever, that a restricted intake of calcium enhances
oxalate absorption and increases urinary oxalate [8,
lii. Furthermore, since most forms of calculous dis-
ease are chronic disorders, serious consideration
should be given to the potentially adverse effects on
the skeleton of a long-term negative calcium balance.
If orthophosphates are to be used in therapy, there is
no evidence that dairy products should be omitted
[121. I advise patients to ingest daily at least one
serving of milk, cheese, or ice cream. As discussed
in Dr. Williams's article (this issue), a large intake of
calcium may be used to decrease urinary oxalate in
those calculous patients with steatorrhea and hyper-
oxaluria, but the amounts of calcium required are so
large that various calcium salts, rather than dairy
products, are advocated [131.
Often patients will be simultaneously taking medi-
cines prescribed by different physicians for their
several disorders. For example, patients for whom
phosphates have been prescribed may have been
directed by another physician to take antacids that
contain phosphate-binding aluminum gels. Thus, pa-
tients should be informed about medicines likely to
niterfere with the therapeutic effect of the prescribed
compound. Barbiturates enhance oxalate formation
from methoxyfiurane and, in experimental animals,
also increase endogenous oxalate formation [141.
Until more is known about such possible effects in
man, it is probably wise to avoid use of barbiturates
in patients with calcareous calculi.
Selection and use of specific phosphatic compounds
Treatment directed toward enhancing "solubility" of
calcium salts in urine
Because many patients (30 to 50%) with idiopathic
calcareous calculi are not hypercalciuric, it is plausi-
ble that the amount of calcium in urine is of second-
ary importance to calculus formation. Furthermore,
patients with hypoparathyroidism treated with vita-
min D and calcium salts are known to have almost no
tendency to develop renal calculi, despite a continu-
ous marked hypercalciuria. Calculus formation is
similarly absent in patients with hyperthyroidism,
who are almost always hypercalciuric, even if such
patients remain untreated for years. These clinical
observations are consistent with the idea that the
amount or concentration of urinary calcium per se is
not the major factor that determines the occurrence
of renal calculi. This notion gained support when
early morning urine specimens from calculous pa-
tients were observed to mineralize rachitic rat carti-
lage in vitro, whereas urine from normal subjects
would not [15]. The difference in the mineralizing
potential of urine from normal and calculous subjects
was not accounted for by differences in their urinary
concentrations of calcium, magnesium, phosphorus, or
citrate [161. Despite the limitation of the technique
used (see Dr. Fleisch's article, this issue), it was
deduced that urine from normal subjects contained
inhibitors of crystal formation and that these inhibi-
tors were deficient in the urine of patients who
formed calcareous calculi [16,171.
Colloidal substances in urine have long been con-
sidered to be important in maintaining in supersatur-
ated solution the various poorly soluble urinary crys-
talloids [18,191. In the previously cited observations
on mineralization of rachitic cartilage by urine, the
results were unchanged when the urine specimens
were ultrafiltered before incubation [161. Thus, uri-
nary constituents accounting for the difference in
mineralizing potential of such speciments must have
been of less-than-colloidal dimensions. Inorganic py-
rophosphate is one low-molecular-weight inhibitor of
crystal formation in urine [201, but the amounts of
this compound excreted by calculous and normal
subjects are similar [211. The major low-molecular-
weight inhibitor of mineralization in normal urine is
an acidic compound with certain properties like
those of citric acid, and it may be the recently de-
scribed phosphocitrate [221 or some other substi-
tuted citrate compound. Like pyrophosphate, this
compound appears to inhibit crystal formation by a
"crystal-poisoning" effect, rather than by formation
of a 1:1 chelate with calcium. Available information
suggests that a deficiency of this citrate-like com-
pound may be a major factor favoring susceptibility
to calculus formation.
Oral administration of either Calgon®, a commer-
cial polyphosphate water conditioner that is largely
hydrolyzed in the intestinal tract, or similar amounts
of phosphate, as orthophosphate salts, were equally
effective in causing calculous patients to excrete
urine that would not mineralize rachitic cartilage in
vitro [23]. Because of these initial observations, a
long-term program was initiated to assess the effec-
tiveness of orthophosphates in patients with recur-
rent calcareous calculi, and results indicate that
these salts are indeed effective in preventing calculus
formation. Administration of certain nonmetaboliza-
ble inhibitors of crystal formation, the diphospho-
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nates, has been suggested to be another possible
means of preventing calculus formation (Fleisch, this
issue); but the initial results with these compounds,
which subsequently will he commented on in more
detail, do not suggest that this form of therapy should
be used 124].
Available preparations and dosage of orthophos-
phate. Orthophosphate salts are available as potas-
sium acid phosphate, neutral mixtures consisting of
potassium and sodium phosphates or potassium
phosphates alone, or an alkaline mixture consisting
of disodium and dipotassium phosphates (Table 1).
All of these preparations have proved effective in
treating patients with recurrent calcareous calculi. In
patients with gastrointestinal disorders, however,
none of the phosphate salts are well tolerated; and
the sodium-containing mixtures may cause an unde-
sirable amount of fluid retention in patients with
hypertension or in women.
Experiences, to date, indicate that 1,500 mg of
phosphorus daily is the minimal effective dosage in
men; but a slightly smaller dosage, 1,250 mg, has
proved adequate in most women. Patients who form
multiple stones (one or more per month) may require
1,750 to 2,250 mg of phosphorus daily to prevent
formation of new calculi. Although administration of
phosphates at six-hour intervals can be shown to be
most effective in altering urine so that it will not
mineralize rachitic cartilage, I have adopted the
more convenient, and therapeutically satisfactory,
schedule of administering the phosphate salts at
eight-hour intervals.
The increase in urinary phosphate of patients
being treated with phosphate salts will be approxi-
mately 65% of the amount ingested 125]. Urinary
calcium of those patients who are hypercalciuric will
be reduced, but oral phosphates induce little change
Table 1. Available preparations of orthophosphate
Amount of
phosphorus
mg
Acid phosphates
Potassium acid phosphate 114 K-Phos®
tablets, mg/tab
Neutral mixture of sodium and potassium phosphates
Tablets, mg/tub 170 Uro-KP-Neutral®
250 K-Phos Neutral®
500 Phosphate Sandoz®
Capsules, mg/cap 250 Neutra-Phos®
Bulk powder, mg/bottle 12,800 Neutra-Phos®
Neutral mixtures of monobasic and dibasic potassium phosphates
Capsules, mg/cap 250 Neutra-Phos K®
Bulk powder, ing/bottle 7,500 Neutra-Phos K®
Alkaline mixtures of dibasic sodium and potassiu,n phosphates
Tablets, mg/tab 250 K-Phos Alkaline®
in calcium excretion of patients who are not hyper-
calciuric. Inorganic pyrophosphate excretion in-
creases two- to three-fold during phosphate therapy,
and the magnitude of this change in the individual
patient apparently depends on the amount of phos-
phaturia induced [21]. In my experience, urinary
excretion of oxalate and magnesium has not consis-
tently changed during phosphate therapy 126] (Table
2). Most investigators have reported that fecal cal-
cium is little changed in patients receiving phos-
phates [3,27—30], but this form of therapy may cause
a slight increase in fecal calcium 130].
Because of the large amount of sodium in the
available mixture of alkaline phosphates, this prepa-
ration is usually reserved for the patient whose dis-
ease cannot be satisfactorily controlled by large
amounts of the neutral salts. Treatment with alkaline
phosphates induces the expected urinary increments
in pyrophosphate and other hydrolyzable inhibitors
of mineralization and also causes an increased excre-
tion of citrate and possibly the citrate-like inhibitor
[25].
'ffictiveness of orthophosphales in preventing
calculi. Data are available on 270 patients (250 from
published reports and 20 previously unreported pa-
tients) who have been treated with orthophosphates
[31—35!. Most of the patients had been treated for
periods of from one to 12 years. In 245 (90%) of these
patients, calculus formation either completely ceased
or was reduced markedly. The reported effective-
ness might have been greater had some of the unre-
sponsive patients been able to tolerate more than
1,500mg of phosphorus daily, or if the investigators
had been aware that alkaline phosphates are more
effective than the neutral or acid salts. Sometimes
patients with preformed calculi will pass them during
the first few weeks of therapy, and occasionally a
renal calculus will disappear (or dissolve?) without
the patient's being aware of having passed a stone. A
few patients, however, will continue to form calculi
regardless of the dosage or type of phosphate.
During the course of treatment, it is prudent to
review the dietary and drinking habits of the pa-
tients. I have seen the beneficial effects of phos-
phates negated in patients who independently decide
to drink large volumes of iced tea or cranberry juice.
Patients also should be cautioned against the surpris-
ingly widespread practice of ingesting gram amounts
of ascorbic acid. Patients who eat a high-protein diet,
and consequently excrete large amounts of uric acid,
constitute a special problem that will be commented
on subsequently. In one carefully composed study,
modest amounts of potassium acid phosphate
(<1,500mg of phosphorus per day) were found to be
Available form Trade name
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Table 2. Effect of neutral and alkaline phosphates on un nary constituentsa
Patient Therapy
.Calcium
mg124 hr
.
Magnesium
mg/24 hr
.Citrate
mg/24 hr
Oxalate
mg124 hr
Phosphorus
mg124 hr
Inhibitor anionsb
Hydrolyzable Stable
1 None 258 94 938 38 699 N D
Neut. Phos. 144 70 1,083 28 2,139 I U
2 None 187 110 547 37 832 N D
Neut. Phos. 113 113 626 42 1,950 I U
3 None 234 121 206 60 1,325 N D
Alk. Phos. 194 147 495 71 2,413 I I
4 None 187 110 547 37 823 N D
Alk. Phos. 99 134 771 46 2,384 I I
a These are urinary values of representative calculous patients during fourth day of control period (dairy-product-free diet) and later during
fourth day of treatment with either a neutral or an alkaline mixture of orthophosphates while the constant diet was continued. The phosphate
mixtures provided 1,500mg of phosphorus daily. Note that in contrast to the effect of neutral phosphates, the alkaline phosphates caused an
increase in urinary citrate and also in the stable inhibitor of mineralization.
Abbreviations used here are: N, normal; D, decreased; I, increased; and U, unchanged.
ineffective in preventing stone formation [36]. The
apparent ineffectiveness of phosphates in this partic-
ular group of calculous patients may have been due
in part to the dosage schedule but possibly also in
part to interfering dietary habits.
Patients with idiopathic calcareous calculi, those
with medullary sponge kidneys, and slightly hyper-
calcemic patients with hyperparathyroidism may be
treated effectively with orthophosphates. Treatment
of the patients with idiopathic calculi has been no
less effective in those with normocalciuria than in
those with hypercalciuria, even though among the
latter patients many will have a demonstrable in-
crease in the absorption of calcium (Smith, this is-
sue) [371. The orthophosphate salts should not be
administered to azotemic patients who are hyper-
phosphatemic or to those who become hyperphos-
phatemic during treatment. Phosphates are also not
indicated for patients with distal renal tubular aci-
dosis and are contraindicated in patients whose cal-
culi are secondary to infection with urea-splitting
bacteria (i.e., those with struvite stones).
Often patients will form mixed calculi consisting
predominantly of calcium oxalate and uric acid.
Some of these patients will have gout, for the inci-
dence of oxalate stones in gouty patients is increased
[381. Occasionally, patients with mixed stones will
be hyperexcretors of urate as a consequence of a
large intake of protein. Lonsdale [391 and others [40—
42] have suggested that crystals of either uric acid or
urate may promote the formation of oxalate crystals,
but whether this process accounts for the frequent
association of uric acid and calcium oxalate in calculi
is uncertain. Patients who form such mixed stones
should be evaluated for the possible presence of
gout, and their dietary habits also should be re-
viewed. It has been my practice to prescribe allopuri-
nol, 300 mg once daily, in addition to orthophos-
phates, for those patients with mixed oxalate and
uric acid stones, or for those with calcium oxalate
stones and hyperuricosuria. Additional discussion of
the interrelation between uricosuria and oxalate
stones is presented in Dr. Coe's article (this issue).
Adverse effects of orthophosphate therapy. Diar-
rhea is the single most troublesome side effect of
orally administered orthophosphates. As mentioned
previously, patients with a peptic ulcer or an irritable
colon usually do not tolerate this form of therapy.
Often, mild diarrhea will occur during the first few
days of therapy but then subside. A persistent diar-
rhea may sometimes be obviated by taking the phos-
phate preparation after, rather than before, a meal.
Dystrophic calcification has been reported as a com-
plication of phosphate therapy in a small group of
Australian patients [43] but has not been observed
by others [44].
As might be expected, orthophosphates induce
mild, dose-related changes in serum concentrations
of calcium and phosphorus. The normal postprandial
decrease in inorganic phosphorus and slight increase
in calcium do not occur if a dose of orthophosphates
has preceded the meal [45]. Reiss and associates [461
noted a transient increase probably related to such
dose-related changes in the serum concentrations of
parathyroid hormone for one to two hours after oral
doses of 1 g of phosphorus (as orthophosphate).
Also, by microradiography, a slight but persistent
increase in bone-resorption surfaces has been noted
in osteoporotic patients receiving supplementary
phosphates [47]. I have found, however, that long-
term orthophosphate therapy for patients with idio-
pathic calculi has caused no change in hydroxypro-
line excretion (unpublished observations).
The sodium-containing mixtures of orthophos-
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phates may cause an exacerbation of blood pressure
in hypertensive subjects; so if orthophosphates are
to be used for this type of patient, the sodium-free,
neutral mixture of potassium phosphates is pre-
ferred. This preparation may also be tolerated best
by female patients who have a tendency to develop
edema,
The diphosphonates. Ethane-hydroxy-diphos-
phonate (EHDP) is a potent inhibitor of the forma-
tion and aggregation of crystalline calcium phosphate
or calcium oxalate [48—50] and has been reported to
be effective in decreasing calculus formation in ex-
perimental animals [51]. Administration of this di-
phosphonate to calculous patients causes some re-
duction in oxalate crystalluria but increases oxalate
excretion [24]. Although the EHDP is poorly ab-
sorbed, the large doses required (20 mg/kg) to mod-
ify crystalluria are sufficient to cause bone disease in
man [52]. Thus, for the present, orally administered
diphosphonates hold little promise of usefulness as
treatment for calcareous calculi.
Treatment directed toward reducing urinary calcium by
limiting absorption
Urinary calculi in uninfected patients usually con-
sist largely of crystalline aggregates of calcium oxa-
late and phosphates and a small amount of proteina-
ceous matrix. In most patients with calcareous
calculi, the magnitude and frequency of urinary su-
persaturation with calcium oxalate and calcium
phosphate is greater than that which occurs in nor-
mal subjects [53, 54]. If the supersaturation of urine
by these poorly soluble crystalloids did not occur,
crystallization, aggregation and, hence, stone forma-
tion should be ameliorated and possibly prevented.
Such a rationale has been applied with apparent
effectiveness in the phosphate deprivation program
for patients with struvite calculi [551. Similarly, a
reduction in urinary calcium should reduce forma-
tion of calcium-containing crystals and thereby be of
therapeutic benefit to patients who form calcareous
calculi. Calcium excretion in urine can be decreased
by limiting dietary calcium while administering com-
pounds that interfere with its intestinal absorption.
Two such compounds that have been evaluated for
usefulness in preventing calculus formation are so-
dium phytate and cellulose phosphate. It is appropri-
ate to review briefly the published experience with
these agents.
Phytic acid. Inositol hexaphosphoric acid, or phy-
tic acid, an important ingredient of cereal grains,
forms insoluble complexes with magnesium and cal-
cium. Because this dietary constituent can reduce
the absorption of calcium [56, 57], the sodium salt
has been used therapeutically to treat hypercalciuric
patients [58, 59]. Boyce, Garvey, and Goven [58]
administered approximately 9.0 g of sodium phytate
per day in divided doses to a large group of calculous
patients; but despite a reduction in urinary calcium,
no definite decrease in calculus formation was ob-
served. This mode of therapy was limited by a lack of
palatability and possibly also by the fact that 50% or
more of administered phytate was hydrolyzed by
intestinal phytases [58, 59].
Cellulose phosphate. This compound is a cellulose
resin that, in the sodium form, contains approxi-
mately 0.1 g of phosphorus per gram of resin. Cellu-
lose phosphate avidly binds divalent cations and has
been advocated as a means of controlling hypercalci-
uria. It is apparently not absorbed and is hydrolyzed
in the intestinal tract to a lesser degree than is phytic
acid [60, 61]. Cellulose phosphate, 5 g two to three
times daily, has been reported to regularly reduce
urinary calcium and magnesium and to increase the
fecal excretion of these cations [60—63]. Urinary
phosphorus is increased by only several hundred
milligrams per day. As with most forms of therapy,
however, certain undesirable consequences could
arise from the use of cellulose phosphate. In addition
to the need of protecting against magnesium deple-
tion, the administration of this compound had been
reported to increase urinary oxalate [64, 651 and
hydroxyproline [631. The slightly augmented hy-
droxyproline excretion has been attributed to an in-
crease in parathyroid hormone secretion [63], but
the reported serum concentrations of this hormone in
treated patients have remained within the normal
range [62].
Until now, experiences with cellulose phosphate
in the long-term treatment of renal calculi are too
limited for us to be confident of the therapeutic
benefits or the absence of undesirable side effects.
Short-term metabolic balance studies have indicated
that treated patients are in zero, positive, or only
slightly negative calcium balance. Although the ef-
fect of celk!ose phosphate on absorption of iron has
not been evaluated, patients have maintained normal
serum iron concentration and have not developed
anemia during treatment. In one group of calculous
patients treated with cellulose phosphate (10 to 15 g
daily with or after meals) and supplements of magne-
sium chloride (117 to 175 mg of magnesium daily in
two divided doses) for 1.5 to 4.8 yr, calculus forma-
tion was markedly decreased [62]. This beneficial
effect was attributed to the reduction in urinary cal-
cium and consequent decrease in the activity product
with respect to brushite (CaHPO4' 2H20) in urine.
Interestingly, the reduction in calculus formation oc-
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curred despite probable increases in urinary oxalate
and secretion of parathyroid hormone. Therefore,
until more is known of the effects of this compound,
it should be used only as has been advocated [621, in
those patients with intestinal hyperabsorption of
calcium.
Conclusion
Until the pathogenesis of renal calculi is fully
understood, the rationale for adopting a particular
form of therapy must be, in part, empirical. Nonethe-
less, such therapy may be highly effective. Cumula-
tive experiences show that orthophosphate salts will
prevent formation of calcareous calculi in most pa-
tients; these salts apparently induce compensatory,
rather than corrective, changes in urine of calculous
patients. A large part of the effectiveness of ortho-
phosphates may be because they enhance the excre-
tion of inhibitors of crystal formation, independent of
any induced changes in calcium excretion. Another
type of phosphate, cellulose phosphate, has been
used as a means of decreasing urinary calcium in
patients with calcareous calculi. This compound is
largely unmetabolized; and because of an avidity for
divalent cations, it provides a means of reducing the
intestinal absorption of calcium. The possible com-
plications from long-term use of cellulose phosphate
are unknown.
Renal calculi occur most often as a manifestation
of a chronic disorder. Therefore, costs, palatability,
and absence of ill effects during long-term treatment
must be considered in selecting a therapeutic agent.
Currently, several modes of treatment are available
for patients with calcareous calculi; but irrespective
of the treatment selected, continuous supervision of
the patients is necessary to detect any adverse ef-
fects and to obtain maximum benefit in preventing
calculi.
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